2014年加拿大不列颠哥伦比亚省麻疹暴发期间肌注免疫血清球蛋白暴露后预防的估计保护效果
2014年加拿大不列颠哥伦比亚省某宗教社区麻疹暴发中,55名自报麻疹易感接触者仅接受肌注免疫血清球蛋白暴露后预防,17人在8-21天内出现临床麻疹,估计粗保护效果为69%;5-18岁学龄儿童估计保护效果为50%。作者认为将加拿大推荐的麻疹肌注免疫血清球蛋白暴露后预防剂量从0.25 ml/kg提高至0.5 ml/kg(最大体积15 ml)可能提高保护效果。
要点
- 55名肌注免疫血清球蛋白暴露后预防接受者中17人发生临床麻疹,估计粗保护效果为69%。
- 5-18岁学龄儿童中估计肌注免疫血清球蛋白暴露后预防保护效果为50%。
- 作者认为将推荐剂量从0.25 ml/kg提高至0.5 ml/kg(最大15 ml)可能提高保护效果。
核心结论
- 肌注免疫血清球蛋白暴露后预防在给药后8-21天内针对麻疹疾病的估计粗保护效果为69%。
- 该估计保护效果的准确性易受暴露细节和暴露前免疫状态确认中的假设与不确定性影响。
- 作者认为将加拿大推荐的麻疹肌注免疫血清球蛋白暴露后预防剂量从0.25 ml/kg提高至0.5 ml/kg(最大体积15 ml)可能提高保护效果。
研究设计与样本
- 2014年加拿大不列颠哥伦比亚省某宗教社区麻疹暴发期间,对55名自报麻疹易感接触者仅提供肌注免疫血清球蛋白暴露后预防。
- 合格期推断为初次麻疹病例暴露后6天内。
- 临床结局通过选择性主动监测和病例自报确定,肌注免疫血清球蛋白暴露后预防失败定义为给药后8-21天出现麻疹样皮疹。
- 对8名接受者检测了暴露后预防后麻疹IgG抗体水平。
- 分析了与麻疹疾病相关的因素。
主要发现
- 55名肌注免疫血清球蛋白暴露后预防接受者中17人在随后8-21天内发生临床一致的麻疹,估计粗保护效果为69%。
- 5-18岁学龄儿童中,估计肌注免疫血清球蛋白暴露后预防保护效果为50%。
- 双变量分析中,年龄<25岁与突破性临床麻疹显著相关(p=0.0217)。
- 在17名被认为暴露后预防失败的接触者中检测了8人,暴露后预防后麻疹IgG抗体水平(平均16.3天,范围16-17天)均<150 mIU/ml。
关键数值与推荐
- 肌注免疫血清球蛋白暴露后预防推荐在初次暴露后6天内给药。
- 加拿大推荐的麻疹肌注免疫血清球蛋白暴露后预防剂量为0.25 ml/kg,最大体积15 ml;作者认为提高至0.5 ml/kg可能提高保护效果。
- 暴露后预防失败定义为给药后8-21天出现麻疹样皮疹。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 该估计保护效果的准确性易受暴露细节和暴露前免疫状态确认中的假设与不确定性影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Intramuscular Immune Serum Globulin (IM ISG) is recommended as post-measles exposure prophylaxis (PEP) when administered within 6days of initial exposure, with variable effectiveness in preventing measles disease. Effectiveness of IM ISG PEP in preventing clinical measles was assessed during a 2014 measles outbreak among a religious-affiliated community in British Columbia, Canada. MATERIAL AND METHODS: Fifty-five self-reporting measles susceptible contacts were offered exclusively IM ISG PEP within an eligibility period best surmised to be within 6days of initial measles case exposure. Clinical outcome of IM ISG PEP recipients was determined by selective active surveillance and case self-reporting. IM ISG PEP failure was defined as onset of a measles-like rash 8-21days post-IM ISG PEP. Post-IM ISG PEP measles IgG antibody level was tested in 8 recipients. Factors associated with measles disease were analyzed. RESULTS: Seventeen of 55 IM ISG PEP recipients developed clinically consistent measles in the following 8-21days, corresponding to an estimated crude protective effectiveness of 69%. In school aged children 5-18years, among whom potential exposure intensity and immune status confounders were considered less likely, estimated IM ISG PEP protective effectiveness was 50%. Age <25years was significantly associated with breakthrough clinical measles in bivariate analysis (p=0.0217). Among 8 tested contacts of 17 considered IM ISG PEP failures, post-IM ISG PEP measles IgG antibody levels (mean 16.3days (range 16-17days) post-PEP) were all <150mIU/ml. CONCLUSIONS: The estimated crude IM ISG PEP protective effectiveness against measles disease within 8-21days post-ISG administration was 69%. Accuracy of this estimated protective effectiveness is vulnerable to assumptions and uncertainties in ascertaining exposure details and pre-exposure immune status. Increasing the Canadian recommended measles IM ISG PEP dose from 0.25 to 0.5ml/kg (up to 15ml maximum volume) may increase protective effectiveness.
引用
- Bigham M, Murti M, Fung C, et al. Estimated protective effectiveness of intramuscular immune serum globulin post-exposure prophylaxis during a measles outbreak in British Columbia, Canada, 2014. Vaccine. 2017. PMID: 28392140. doi:10.1016/j.vaccine.2017.03.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。